References
- Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Human Reproduction 2000; 15: 526–531
- Baird DT. Factors regulating the growth of the pre-ovulatory follicle in sheep and humans. Journal of Reproduction and Fertility 1983; 69: 343–352
- Bergh, C, Broden, H, Lundin, K, et al. Comparison of fertilization, cleavage and pregnancy rates of oocytes from large and small follicles. Human Reproduction 1998; 13: 1912–1915
- De Jong D, Macklon NS, Eijkemans MJC, Mannaerts BMJL, Coelingh Bennink HJT, Fauser BCJM, the Ganirelix Dose-Finding Study Group. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertility and Sterility 2001; 75: 688–693
- Ectors, E, Vanderzwalmen, P, Van Hoeck, J, et al. Relationship of human follicular diameter with oocyte fertilization and development after in vitro fertilization or intracytoplasmic sperm injection. Human Reproduction 1997; 12: 2002–2005
- European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 2001; 16: 644–651
- European Orgalutran Study Group, Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 2000; 15: 1490–1498
- Fleming R, Coutts JRT. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertility and Sterility 1986; 45: 226–230
- Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature lutcinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 1998; 13: 3023–3031
- North American Ganirelix Study Group, Fluker, M, Grifo, J, Leader, A, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 2000; 75: 38–45
- Oberyé JJL, Mannaerts BMJL, Kleijn H-J, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertility and Sterility 1999; 72: 1001–1005
- Thomas N, Goodacre R, Timmins EM, Gaudoin M, Fleming R. Fourier transform infrared spectroscopy of follicular fluids from large and small antral follicles. Human Reproduction 2000; 15: 1667–1671
References
- Tan SL, Balen AH, Hussein EE, Mills C, Campbell S, Yovich J, Jacobs HS. A prospective randomized study of the optimum timing of human chorionic gonadotrophin administration after pituitary desensitisation in in vitro fertilisation. Fertility and Sterility 1992; 57: 1259–1264
- van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in vitro fertilization treatment cycle in low responders: a randomized study. Human Reproduction 1993; 8: 369–373